Navigation Links
Biomaterial banks for research -- clear strategies and recommendations needed
Date:4/18/2011

This release is available in German.

Biomaterial banks are an indispensable resource for biomedical research. They are of great importance to the quality and competitiveness of German research. Therefore, it is important that clear strategies and recommendations exist for Germany. At present however, no general comprehensive statutory regulations, in the form of a research biobank act, should be introduced.

This is the conclusion of a joint statement by two Senate Commissions of the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation): the Senate Commission on Clinical Research and the Senate Commission on Genetic Research. The statement was initiated with regard to the current debate on legal regulations of human biobanks and represents the DFG's contribution to and commentary on the statement by the German Ethics Council "Human Biobanks for Research".

The DFG Senate Commissions propose that, instead of an overarching set of legal regulations, observance of the principles contained in the recommendations of the Ethics Council, based on the existing legal framework for large biobanks, is to be encouraged. These principles include the specification of permissible usage, the involvement of ethics committees, quality assurance in data protection and transparency of the goals and operating procedures of a biobank. The DFG Senate Commissions further propose that the observance of these principles should be made a prerequisite for the funding of biobanks by the DFG and other public funding bodies. In the opinion of the DFG Senate Commissions, there should be no tightening of the requirements for smaller biomaterial banks.

To the DFG Senate Commissions, separate secrecy protection for biobanks does not appear to be necessary at present and would be unique internationally. Any new relevant legislation could prevent international cooperation and hinder biomedical research in Germany.

Wording of the Statement by the DFG Senate Commissions

Biomaterial banks are an indispensable resource for biomedical research; coordinated, quality-assured and sustainable biomaterial banking is a long-term scientific structural objective, which is essential to the quality and competitiveness of German research. Therefore, it is important for Germany that clear strategies and recommendations for biobanks exist. The DFG, as a substantial funder of biomedical research, is taking an active part in discussions on the future structure of biobanking in Germany and on the regulations that are relevant to it.

1. The DFG Senate Commission on Clinical Research and the DFG Senate Commission on Genetic Research expressly welcome the statement by the German Ethics Council "Human Biobanks for Research". On many issues it represents the "gold standard" for biomaterial banks and is a suitable approach for placing research biomaterial banks on a sustainable and coordinated basis in the long term that is accepted by all stakeholders.

2. Already, large existing and planned biomaterial banks can fulfil the requirements of the German Ethics Council without legal regulation (for example National Cohort, PopGen , tissue bank of the Nationales Centrum fr Tumorerkrankungen (National Centre for Tumour Diseases, NCT) , tissue banks of the Network of Comprehensive Cancer Centres). In principle however, these requirements place a considerable, not to mention financial, constraint on the biomaterial banks, which has not been adequately represented in the available structural funding up to now.

3. For many relevant biomaterial banks which do not have the necessary resources at their disposal, the formal requirements in the statement by the German Ethics Council are very high and thereby threaten their continued existence. On the other hand, in the interests of all stakeholders the donors, the host institutions and research there is a general need to optimise these biomaterial banks for scientific use as well.

4. Project-specific collections that are relatively small, for example those of doctoral and postdoctoral researchers, are of specific importance for university-based research. If they were to be subject to a biobank law, that would surely overstretch their organisational capacity. However, if these collections are excluded from the regulatory scope of such a law, this runs counter to sustainability considerations in relation to biobanks. To ensure that the samples and data remain accessible for further use after completion of the project, they should ideally be included in a larger biomaterial bank that is structurally and technically well equipped. In this case the samples and data would again fall under the regulatory scope of a biobank law, and this at a time when most of the requirements of such a law could no longer be satisfied. From this immediately follows the necessity to draw up a strategy that is tailored to the needs of project-specific collections, before committing to a fixed legal framework.

5. The biobank secrecy being discussed in Germany takes a very specific aspect of the operation of biobanks into account. Since in general no comparable protection regulations exist in other countries, such a move could have negative consequences with regard to the increasing number of international collaborations and joint research programmes, as well as competitive disadvantages in comparison to research carried out abroad. Furthermore, the extensive regulations on data protection and medical privacy in the context of biobanks already guarantee a very high level of protection for research in international comparison.

6. Proposal by the Senate Commissions

  • At present no general and comprehensive statutory regulation, in the form of a research biobank act, should be introduced. Instead, observance of the principles contained in the recommendations of the Ethics Council is to be encouraged on the basis of the existing legal framework for large biobanks. This could be implemented effectively by making the observance of these principles a prerequisite for the funding of biobanks by the DFG and other public funding bodies. In addition data protection authorities and ethics commissions should require and monitor the observance of the guidelines.

  • Conversely, it is necessary to provide sufficient funds for biomaterial banks in order to ensure over the long term both a high-quality biobanking facility as well as the implementation of the current rules. Unified strategies are necessary at the various participating institutions to ensure this.

  • For smaller biomaterial banks there should be no tightening of the requirements in accordance with the minority statement by the German Ethics Council. Strategies are to be developed that also tie these smaller biobanks into secure structures for the purpose of optimising their usage.

  • Separate secrecy protection for biobanks does not appear necessary at present and would be unique internationally. Any new relevant legislation risks jeopardising international cooperation and biomedical research in Germany.


'/>"/>

Contact: Dr. Eva-Maria Streier
em.streier@dfg.de
49-228-885-2250
Deutsche Forschungsgemeinschaft
Source:Eurekalert

Related biology news :

1. UBC researchers design new biomaterial that mimics muscle elasticity
2. Crab claws pack strengthening bromide-rich biomaterial
3. TECNALIA investigates advanced biomaterials to make more reliable and hardwearing medical implants
4. Last sample collected for one of the worlds deepest biobanks
5. NOAA report finds flower garden banks sanctuary reefs among healthiest in Gulf
6. First cGMP feeder-independent pluripotent stem cell banks released for distribution
7. Researchers get a first look at the mechanics of membrane proteins
8. Jefferson researchers unlock key to personalized cancer medicine using tumor metabolism
9. NIH researchers complete whole-exome sequencing of skin cancer
10. Scripps Research scientists identify mechanism of long-term memory
11. Lesser-known Escherichia coli types targeted in food safety research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
(Date:3/27/2017)... March 27, 2017  Catholic Health Services (CHS) ... Systems Society (HIMSS) Analytics for achieving Stage 6 ... sm . In addition, CHS previously earned a ... using an electronic medical record (EMR). ... level of EMR usage in an outpatient setting.  ...
(Date:3/24/2017)... Research and Markets has announced the addition ... Trends - Industry Forecast to 2025" report to their offering. ... The Global Biometric ... of around 15.1% over the next decade to reach approximately $1,580 ... market estimates and forecasts for all the given segments on global ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... 2017 , ... DuPont Pioneer and recently formed CasZyme, a ... a multiyear collaboration to identify and characterize novel CRISPR-Cas nucleases. The goal of ... across all applications. , Under the terms of the agreement, Pioneer will provide ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... President Andi Purple announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief ... ), Inc. has been selected for membership in ARCS Alumni Hall of ...
(Date:10/11/2017)... BioMarketing, a leading provider of patient support solutions, has announced ... network, which will launch this week. The VMS CNEs will ... to enhance the patient care experience by delivering peer-to-peer education ... professionals to help women who have been diagnosed and are ... ...
(Date:10/10/2017)... DIEGO, CALIF. (PRWEB) , ... October 10, 2017 , ... ... as part of its corporate rebranding initiative announced today. The bold new look ... its reach, as the company moves into a significant growth period. , It will ...
Breaking Biology Technology: